Pd-1 deficient mice and the use
CA 2429042 C · Owner: Nishimura, Hiroyuki · Inventors: Honjo, Tasuku; Nishimura, Hiroyuki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It relates to BALB/c mice that defect programmed cell death-1 receptor (PD-1), a screening method of autoimmune disease medicine by use of these mice, IgG self-reactivity antibody that the mice produce specifically protein , specifically, reacted to the antibody and produced in heart and an diagnostic method in , dilated, cardiomyopathy by use of the protein. Because PD-1 deficient BALB/c mice spontaneously develop autoimmune disease, specifically dilated cardiomyopathy they are useful to screening for, medicines against these diseases.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 14, 2001 and granted September 25, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 14, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 14, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.